2 results
Approved WMORecruiting
To demonstrate safety and efficacy of Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DESin wide clinical use.
Approved WMORecruiting
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…